Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2007

Bayer Schering Taps VTT to Study Cancer Drug

  • VTT and Bayer Schering Pharma will collaborate to study the mode of action of a Bayer’s new cancer drug. As part of this two-year research contract, VTT will use its new gene and cell biology methods.

    VTT’s focus is on identifying primary driver genes and targets of genetic alterations in cancer. The company also works toward finding drug compounds preventing the growth and metastasis of breast and prostate cancer.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »